Dexcom Shows Off More G7 Data
Executive Summary
The newly published data solidifies the G7 as an improvement over the G6 and supports its potential as a 14-day wearable.
You may also be interested in...
ATTD 2022: Dexcom EVP Discusses New Portfolio, Research, Increasing The Market Of CGMs
Chad Patterson, Dexcom’s executive vice president of global marketing and product management, talked to Medtech Insight about the premium continuous glucose monitor manufacturer’s plans for facing stiff competition over the coming years.
Dexcom Plans European Launch Of G7 CGM; Hopes To Earn 510(k) This Summer
Dexcom received a CE mark for the G7 system in Europe and is awaiting a 510(k) clearance from the US FDA. The G7 is smaller and easier-to-use than the company's G6 CGM and will be more competitive with Abbott's FreeStyle Libre 3 CGM
Dexcom G6 Finally Gets Official Classification
After nearly four years of treating the Dexcom glucose monitoring system as moderate-risk class II, the US FDA made the designation official.